Back to top

Analyst Blog

Biopharma company AbbVie (ABBV - Analyst Report) has signed a worldwide license agreement with Belgian company Ablynx for the development and commercialization of the latter’s autoimmune disease candidate, ALX-0061.

The deal, worth more than $840 million, includes an upfront payment of $175 million. AbbVie could make additional payments of up to $665 million on the achievement of development, regulatory, commercial and sales-based milestones. Ablynx is also entitled to double-digit tiered royalties on net sales upon commercialization.

ALX-0061, an anti-IL-6R Nanobody, is being evaluated for the treatment of inflammatory diseases. Results from a phase IIa study showed strong efficacy and safety in patients with moderately to severely active rheumatoid arthritis (RA) on a stable background of methotrexate.

Phase II development for RA and systemic lupus erythematosus (SLE) will be handled by Ablynx. Ablynx will use a part of the $175 million upfront payment for the same. AbbVie will exercise its right to in-license ALX-0061 depending on the achievement of certain pre-defined success criteria.

Once AbbVie in-licenses the candidate, it will be responsible for phase III development and commercialization. Co-promotion rights in Belgium, the Netherlands and Luxembourg will be retained by Ablynx.

Our Take

AbbVie, which has a strong presence in the autoimmune disease market thanks to its blockbuster drug, Humira, should make a strong development and commercialization partner for Ablynx.

Meanwhile, this deal is in line with AbbVie’s efforts to expand and strengthen its autoimmune disorder pipeline. Earlier this year, the company had extended its agreement with biotech company, Galapagos NV, for the development of autoimmune disease candidate, GLP0634, for Crohn’s disease in addition to RA. AbbVie also signed a deal with Alvine Pharmaceuticals for the global development of a novel oral treatment for patients with celiac disease, an autoimmune disease.

AbbVie currently carries a Zacks Rank #3 (Hold). While we are positive on AbbVie’s strong late-stage pipeline, dividend yield and growth strategy, we remain concerned about its dependence on Humira. We believe AbbVie will continue pursuing in-licensing deals and collaborations to boost its pipeline.

At present, large-cap pharma companies like Roche (RHHBY - Analyst Report), Novo Nordisk (NVO - Analyst Report) and Bayer (BAYRY - Analyst Report) look well-positioned. While Roche is a Zacks Rank #1 (Strong Buy) stock, Novo Nordisk and Bayer are Zacks Rank #2 (Buy) stocks.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.48 +6.16%
BITAUTO HOL… BITA 81.71 +5.12%
CHINA BIOLO… CBPO 48.00 +3.49%
CTPARTNERS… CTP 16.49 +3.19%
STRATTEC SE… STRT 73.90 +3.15%